Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04514484 · OUTCOME

Human Immunodeficiency Virus (HIV) Viral Loads

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
copies/mL
Interval / dispersion
Full Range
Time frame
Up to 8 weeks from start of combination treatment

What was measured

HIV viral loads at treatment Cycle 2.

Analysis population: Treated patients who provided samples for HIV viral load testing.

Groups in this outcome

Treatment (Cabozantinib S-malate, Nivolumab)

Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Cabozantinib S-malate, Nivolumab)2

Reported measurements

Source class 1
Values in copies/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Cabozantinib S-malate, Nivolumab)20Not reported029.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        29.0
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
HIV viral loads at treatment Cycle 2.
dispersion Type
Full Range
groups
  1. description
    Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
    id
    OG000
    title
    Treatment (Cabozantinib S-malate, Nivolumab)
param Type
MEDIAN
population Description
Treated patients who provided samples for HIV viral load testing.
reporting Status
POSTED
time Frame
Up to 8 weeks from start of combination treatment
title
Human Immunodeficiency Virus (HIV) Viral Loads
type
SECONDARY
unit Of Measure
copies/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice